(AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $10 million in its third quarter.
Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase
Black Diamond Therapeutics maintains a strong cash position, sufficient to fund operations into H2 2028. I rate BDTX stock as Buy. Read my complete analysis.
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Gl
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.